CN1695608A - Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell - Google Patents
Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell Download PDFInfo
- Publication number
- CN1695608A CN1695608A CN 200410037860 CN200410037860A CN1695608A CN 1695608 A CN1695608 A CN 1695608A CN 200410037860 CN200410037860 CN 200410037860 CN 200410037860 A CN200410037860 A CN 200410037860A CN 1695608 A CN1695608 A CN 1695608A
- Authority
- CN
- China
- Prior art keywords
- cell
- ischemia
- group
- plain
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 12
- 201000010099 disease Diseases 0.000 title claims abstract description 11
- 229940079593 drug Drugs 0.000 title abstract description 12
- RTIXKCRFFJGDFG-UHFFFAOYSA-N Chrysin Natural products C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 title abstract 2
- FGUBFGWYEYFGRK-HNNXBMFYSA-N Pinocembrin Natural products Cc1cc(C)c2C(=O)C[C@H](Oc2c1)c3ccccc3 FGUBFGWYEYFGRK-HNNXBMFYSA-N 0.000 title abstract 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 title abstract 2
- URFCJEUYXNAHFI-ZDUSSCGKSA-N pinocembrin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=CC=C1 URFCJEUYXNAHFI-ZDUSSCGKSA-N 0.000 title abstract 2
- 210000002569 neuron Anatomy 0.000 title description 19
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract description 45
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 44
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims description 17
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000005779 cell damage Effects 0.000 claims description 10
- 208000037887 cell injury Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 210000003061 neural cell Anatomy 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 abstract description 17
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 52
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 48
- 235000011613 Pinus brutia Nutrition 0.000 description 48
- 241000018646 Pinus brutia Species 0.000 description 48
- 208000028867 ischemia Diseases 0.000 description 38
- 241000700159 Rattus Species 0.000 description 37
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 30
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 30
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 30
- 239000011575 calcium Substances 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 25
- 108010074051 C-Reactive Protein Proteins 0.000 description 24
- 102100032752 C-reactive protein Human genes 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 230000000302 ischemic effect Effects 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 18
- 210000001320 hippocampus Anatomy 0.000 description 18
- 102000007590 Calpain Human genes 0.000 description 16
- 108010032088 Calpain Proteins 0.000 description 16
- 230000002490 cerebral effect Effects 0.000 description 16
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 15
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 230000007246 mechanism Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 description 12
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 229910001424 calcium ion Inorganic materials 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 210000003657 middle cerebral artery Anatomy 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- 238000004043 dyeing Methods 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- -1 flavone compound Chemical class 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 210000001130 astrocyte Anatomy 0.000 description 8
- 230000032696 parturition Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000035939 shock Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000006978 adaptation Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 101150031823 HSP70 gene Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002461 excitatory amino acid Effects 0.000 description 3
- 239000003257 excitatory amino acid Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical group [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 230000004693 neuron damage Effects 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 206010053682 Brachycephaly Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000009283 Craniosynostoses Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008564 D-lysines Chemical class 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 108050008339 Heat Shock Transcription Factor Proteins 0.000 description 1
- 102000000039 Heat Shock Transcription Factor Human genes 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000006447 Phospholipases A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 102100027287 Serpin H1 Human genes 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003591 cerebellar nuclei Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 108010055409 ganglioside receptor Proteins 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- RDZTWEVXRGYCFV-UHFFFAOYSA-M sodium 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonate Chemical compound [Na+].OCCN1CCN(CCS([O-])(=O)=O)CC1 RDZTWEVXRGYCFV-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An application of pinocembrin in preparing the medicines for preventing and treating cerebral ischemia and its sequelae, and the diseases associated with the injury and function variation of neurocyte is disclosed.
Description
Technical field
The present invention relates to give birth to Song Suhe and contain the application in relevant disease medicines such as preparation prevention and treatment cerebral ischemia, cerebral ischemia sequela, neural cell injury and changing function of giving birth to the plain compositions of pine.
Background technology
Along with expanding economy, the raising of health care level, aged crowd significantly increases, and cerebrovascular disease such as apoplexy have become one of major disease of serious harm human health, and its sickness rate, disability rate and mortality rate are all very high; Patient more back quality of life relatively poor, take medicine throughout one's life, make troubles and heavier financial burden for patient's life.As: in 2000, U.S.'s patients with cerebral apoplexy reached 4,000,000 person-times, and annual medical total expenses reaches 4,000,000,000 dollars, on average 10,000 U.S. dollars for each person every year.
Brain is an organ extremely responsive to ischemia, the dysfunction that energy shortage causes in case ischemia promptly occurs.If the situation of ischemia fails to improve, then dysfunction continues to spread, and causes cerebral infarction, i.e. the cascade reaction of cerebral ischemia.Present brain injury protection medicine has calcium channel blocker, has been widely used in the treatment of ischemic cerebrovascular as nimodipine; Free radical scavenger (tocopherol, SOD); Neurotrophic factor (nerve growth factor, neurotrophic factor); Nmda antagonist; Ganglioside and excitatory amino acid receptor antagonists etc.
To the treatment of acute ischemic cerebral apoplexy, still lack medicine preferably both at home and abroad.The medicine of present clinical use can't effectively be corrected the symptom of cerebral ischemia, improve after the cerebral ischemia more after.U.S. FDA was ratified first and is treated this sick thrombolytic medicine t-PA in 1996, because the high untoward reaction of intracranial hemorrhage is arranged, and still disputable to its curative effect.Result of study to all kinds cerebral protective agent shows that a lot of clinical drug curative effects are good inadequately, or have than serious side effects.Several medicines are arranged still in the clinical verification stage.Pharmacy worker is always in the medicine effort that can fundamentally treat cardiovascular disease for searching.Therefore the protection medicine of apoplexy is effectively treated in exploitation, and market prospect is wide.
Give birth to loose element and belong to flavone compound, be widespread in nature, chemical structural formula is as follows:
Pharmacological evaluation in the past shows that it has stronger antibacterial, antiviral, antifungal activity.Give birth to the pine element as just being rich in the traditional health food Mel of China, often edible Mel does not only have obstruction to tooth; can also in the oral cavity, play the effect of sterilizing; can alleviate oral ulcer, and accelerating wound healing, but it does not see as yet that to the cerebral ischemia protection someone reports.
Summary of the invention
The invention provides the loose element of giving birth to shown in the formula (I) and protect the application in the medicine at the protection of preparation cerebral ischemia brain injury, treatment cerebral ischemia sequela, neural cell injury.
The present invention is by having carried out a series ofly experimental results show that it is the active drug of cerebral ischemia, cerebral ischemia sequela and neural cell injury protection to giving birth to loose element.
The rat cerebral ischemia experimentation proves, it is plain that pine is given birth in the injection of animal brain ischemia posterior vein, the dyskinesia that cerebral ischemia is drawn, ability of learning and memory goes down and behavioristics's change all improves significantly, improve rat behavior and learn index, the significant prolongation rat is in the time of staying of hang plate, helps promoting the recovery of the various symptoms that cause behind the animal brain ischemia.
The later on visible tangible ischemic necrosis of cerebral tissue of animal brain ischemia; ischemic tissue's volume and degree of ischemia have substantial connection; it is plain to give birth to pine behind the ischemia; the ischemic tissue of brain degree of injury is alleviated; the cerebral ischemia area dwindles, and giving birth to the plain Action Specification that obviously reduces cerebral infarct size of pine has significant protective effect to ischemic tissue of brain.
Experimental result proves that it is plain to give birth to pine behind the animal brain ischemia, can suppress ischemic tissue of brain LDH and discharge; suppress the active rising of Calpain in the ischemic tissue of brain; suppress c reactive protein level rising in the serum, therefore, giving birth to loose element is a valuable cerebral ischemia protection medicine.
Neuronal cell cultures result shows that it is plain for extrinsic factor such as H to give birth to pine
2O
2The neural cell injury that processing causes has significant protective effect; can improve cell survival rate; reducing the release of the lactic acid dehydrogenase that cell causes because of damage, can reduce the cell free calcium ion concentration, is the main mechanism of giving birth to the effect of the plain performance of pine neurocyte protection.
C-reactive protein (CRP) is a kind of acute phase protein.CRP is a kind of very ancient protein on system takes place, and in the evolution of long period of time, CRP is retained, and shows that it has important biological significance.It is generally acknowledged that CRP is a member in the body defending system.Detect CRP clinically and be mainly used in and diagnose the illness, estimate curative effect; It has multiple effects such as activating complement, adjusting immunity.Content is atomic in the normal serum, and in the inflammation acute stage, among the patients serums such as rheumatic fever, rheumatoid arthritis, malignant tumor, wound, CRP content can thousand times of increases.Because it is fast, responsive, objective that CRP reacts, and often CRP is applied to declaring of disease condition as an index clinically and estimates, and understands course of disease process and direction of medication usage.CRP increases the danger that can increase cerebral infarction
[11]Result of study shows, CRP raise with apoplexy after release, cardiovascular complication, infection, the malignant tumor of inflammatory mediators relevant with deep venous thrombosis
[12]The rising of operation group CRP, and due to the unprovoked operation wound, and derive from the reaction of infarction lesion itself, the CRP variable quantity is observed in this experiment simultaneously and neurological's symptom is proportionate, prompting CRP can be used as the early signal of the instantaneous damage of cerebral infarction, and promptly CRP raises and can be used as one of sign of MCAO model success
[13], the result of this and wes' ischemia model group is very approaching, and discovers: pre-adaptation can be improved the CRP that ischemia causes and raise.CRP is by a large amount of acute reaction albumen that the excretory cytokine of activated macrophage stimulates and inducing hepatocyte produces, and obviously increases suppressor T cell and enhancing T miscellaneous function when inflammation or disorganization; Promote leukocyte motion and phagocytic function.It is by combining with lipoprotein, and producing in a large number eventually by classical pathway activating complement system, last albumen and complex cause the tunica intima damage.This may be that pre-adaptation has alleviated the inflammation initial reaction so caused the CRP level to reduce.This provides a frontier to the pre-adaptation Mechanism Study.We find simultaneously: giving birth to loose plain high dose has inhibitory action to c reactive protein level rising in the serum.This prompting: living loose element may react by inflammation-inhibiting brings into play the cerebral ischemia protective effect.
In recent years, the relevant effect of Calpain in cerebral ischemia becomes a new research focus.Calpain is a kind of activatory neutral protease of calcium ion that needs, and is distributed widely in the different tissues that comprises cerebral tissue
[14]In the quiescent stage cell, the major part of Calpain exists with the zymogen forms of non-activity.Because the temporary transient or partial calcium summation of cell, fraction is activated, and certain target substrate molecule is produced limited proteolysis.The cerebral ischemia Calpain activity that can raise, and cause following damage cascade reaction: short ionizing glutamate receptor overactivity on (1) postsynaptic membrane makes Na
+And Ca
2+Continue to flow into cell; (2) Na
+The film depolarization is induced in inflow, opens by voltage-controlled Ca thereupon
2+Passage, and then increase Ca
2+Flow into; (3) Ca in the neuron
2+Continue to be increased to high concentration; (4) depend on Ca
2+System (comprise calmodulin, CaM, Protein kinase C, lecithinase C and A
2, depend on kinases II, nitricoxide synthase and the Calpain of calmodulin, CaM by overactivity; (5) these processes some or all neuron has been produced irreversible damage finally causes cell death
[15]Albuminolysis due to reports such as Bartus, Calpain activate is a potential pathological process of global brain ischemia, and the inductive albuminolysis of Calpain is very fast behind ischemic injuries promptly to be occurred, far away early than can detected infarction on the pathology.Because Calpain is a kind of calcium-activated protease, its activation degree and cytosolic free calcium level are proportionate.So infer: loose plain high dose reduction Calpain activity is handled, given birth to pre-adaptation may be relevant with reduction cytosolic free calcium level.Kitagawa etc.
[16]Studies show that: behind rat or the mouse brain ischemia, Calpain is easy to be activated, and causes Proteolytic enzyme to increase, and this is likely one of reason of neuron rapid wear.
Nitric oxide under the physiological status (NO) plays many-sided important function as a kind of neurotransmitter or courier's material of reversibility disperse in central nervous system (CNS), for example blood vessel dilating, inhibition platelet and leukocyte recruitment.NO also is a kind of free radical and cytotoxic substance simultaneously, can pass through NO-iron complexes, sulfydryl protein oxidation formation superoxide anion generation neurotoxicity.Can improve antiotasis because loose element is given birth in our previous work prompting, and NO can vasodilator, improve the blood supply of cerebral tissue, so we has studied the plain influence to rats with cerebral ischemia homogenate NO level of living pine.NO role in the ischemic cerebral lesion is the emphasis of research always.Although still there is not clear conclusions so far, there is any to affirm, promptly the effect of NO is dual in the brain
[17], its brain protection mechanism can realize by following approach: (1) regulates rCBF; (2) antiplatelet and leukocytic adhesion; (3) downward modulation nmda receptor; (4) the regulation and control mediator discharges; (5) to the feedback regulation of self NO synthase (NOS).Its neurotoxicity mechanism has: (1) mediation toxicity of excitatory amino acid; (2) suppress mitochondrial function; (3) free radical generates and suppresses by free radical the reuptake of excitatory amino acid; (4) generation of peroxynitrite; (5) suppress dna replication dna and reparation.For illustrating the effect of NO, in recent years, many scholars use different no inhibitor treatment ischemic cerebral lesion, but the result of gained is not quite similar, or conflicting
[18], this may illustrate present we the rule that produces in the double action mechanism of NO and the ischemia process and change is also lacked enough understanding.This research finds that by homogenate behind the rat cerebral ischemia is detected the NO level cerebral ischemia can promote NO to discharge.This may be because intracellular calcium concentration increase behind the ischemia activates cNOS by calmodulin, CaM and causes NO generation increase.But in experiment, do not find the influence of pre-adaptation processing or medicine, give birth to plain other blood vessel dilating mechanism of passing through of pine probably, increase tissue perfusion, the damage of minimizing apoplexy NO.
Lactic acidosis is the common trait of ischemic tissue of brain.The hydrogen exchange body of sodium is activated when hanging down pH.Present evidence shows: the hydrogen exchange body inhibitor of sodium also has the better protect effect to cerebral ischemia: significantly reduce infarct size; improve degree of cerebral edema, suppress arachidonic release, motor function is strengthened; excitatory amino acid discharges and reduces, and the neuron loss number reduces
[7-11]The hydrogen exchange body of sodium can be regulated the pH of glial cell, improves more remarkable to the pH under the pathologic condition.When anoxia, use the hydrogen exchange body inhibitor of sodium can improve the energy supply of glial cell
[12]The hydrogen exchange body of sodium is higher at astrocyte film surface content
[13-15]And when In vitro culture, astrocyte can continuous passage.Therefore select for use astrocyte to set up the high flux screening model of the hydrogen exchange body inhibitor of sodium as the donor of the hydrogen exchange body of sodium.
The feature of brain tolerance is that multiple special gene is expressed (referring to gene as c-fos, c-jun, zinc) in the inducing cell, grow out of nothing synthetic or increase relevant stress protein (as Fos albumen, heat shock protein HSP), normal protein matter synthetic then is suppressed or stops.(heat shockproteins is a kind of of stress protein HSP) to heat shock protein, and molecular weight is between 7~200KD.HSP has multiple again, for example HSP27, HSP47, HSP70, HSP90 etc.In most of biologies, HSP70 is abundant, the most conservative stress protein of content and molecular chaperones
[19,20]In eukaryote, multiple HSP70 associated protein is arranged, wherein some is can constitutive expression under the normal growth condition, and is that normal growth is requisite, remaining then can only stress the time just can induce synthetic
[21,22]Under the mammalian cell stress state, HSP70 mRNA is (heat shocktranscription factor, activation HSF) and changing because the heat shock conversion factor.Its mechanism is that stressors is induced formation HSF, and the heat shock combination of elements in HSF and the HSP70 gene promoter begins to change, and HSP70mRNA is converted to the synthetic HSP70 albumen of endochylema, and combines to keep protein from steady with denatured protein in endochylema
[23]HSP70 enters karyon and combines with ribosomal precursor and other nuclear protein, prevents that degeneration from causing the disorder of cell life-information.Suppressed otherwise HSP70 albumen is synthetic, the change of the release of excitatory neurotransmitter and DNA self sequence finally causes the necrosis of neuronic tardy property in addition
[24]Heat tolerance phenomenon has also clearly demonstrated the endogenous Neuroprotective Mechanisms of HSP.When injecting the HSP antibody of anti-70kD in the individual cells, cell loses the heat tolerance; When HSP gene expression was by competitive inhibition in the cell, cell lost the heat tolerance equally.
In the experimental cerebral ischemia, find that by immunocytochemistry these HSP mainly are distributed in neuron, some expression are also arranged at glial cell and endotheliocyte.Focal ischemia handles can cause the proteic expression of cortex Hippocampus CA1 district neuron HSP70, but its weak strength.Studies show that HSP70 albumen expresses in ischemia 5d, expression decreased so that disappear in the 7d-14d in ischemia cortex
[25]In recent years studies show that almost detect in the normal brain activity less than HSP70 mRNA or HSP70, behind transient cerebral ischemia, the Denatured protein of damaged cell can be induced HSP70 gene expression, also obtain an of short duration opposing simultaneously damaging subsequently.This result of study shows, same rat own control finds in the ischemia side cerebral tissue that HSP70 expresses, do not see in the non-ischemia side cerebral tissue that HSP70 expresses, show that cerebral ischemia can induce HSP70 to express, it is the impaired index of reliable cerebral ischemia that HSP70 expresses, and this is consistent with relevant report.
Kitagawa etc. studies show that the synthetic of HSP70 is that the ischemia tolerance is essential, and the expression persistent period of HSP70 and the persistent period basically identical that tolerates effect
[26-28]The proteic expression of HSP is consistent with the susceptibility of selective brain ischemia, at first at CA1, secondly at cortex and thalamus, afterwards in the stronger zones of resistance such as dentate nucleus granulocytes.The HSP that is mainly 70kD continues to raise in ischemia tolerance brain, and expression pattern is consistent with " dose response " and the time window of ischemia tolerance.Because it is especially responsive that Hippocampus CA1 district neuron stimulates ischemia, damage easily behind the ischemia, therefore more to the research of Hippocampus CA1 district neuron ischemia tolerance phenomenon
[29]After pre-adaptation was handled, cerebral cortex and the proteic expression of Hippocampus CA1 district neuron HSP70 significantly increase, and be consistent with cerebral infarct size and behavioristics's index, and prompting HSP70 protein expression and the effect of its organization protection are closely related.
Experiment in vitro proves: HSP70 and HSP27 increase can protect cell
[30]The possible mechanism of action: suppress proteic synthetic in the heat shock process, proteic amount not folding in the eukaryotic cell is reduced, thereby weaken the destruction of pair cell.The synthetic need of eukaryotic protein forms initial medicated cap complex eLF4F, and HSP27 can combine with the constituent eLF4G of eLF4F, stops the translation of mRNA, and pair cell shields
[31]HSP27 can prevent the destruction of Actin, safeguards the stable of cytoskeleton, increases the toleration to heat
[32]Stimulate RNA and proteinic synthetic after heat shock, helper cell was repaired the damage that heat shock causes before death, make cell recover normal physiological function as early as possible.We test discovery: Heat shock protein 27 HSP27 belt leather layer behind ischemia is expressed to some extent and is risen after the pretreatment.Report: Heat shock protein 27 HSP27 is expressed at astrocyte to be increased, and may be the reaction of glial cell to neuronal damage, helps contiguous neuronic survival
[33]
Former study finds to use sympatheticomimetic thing amphetamine can induce HSP27, and HSP70 and HSP89 are expected to be used for inducing of pre-adaptation in the expression of heart, lung, liver, kidney and brain
[34]The thrombin of intracerebral injection low dosage can be induced the great expression of HSP27, and the performance protective effect
[35]Our result of study is found: give birth to the plain high dose of pine and can induce cerebral cortex and the proteic expression of Hippocampus CA1 district neuron HSP70 significantly to increase, HE coloration result showed cell form and number all are protected simultaneously; Point out living pine to have and to bring into play protective effect by inducing the HSP70 protein expression.Its mechanism may be to give birth to the plain ischemia cell HSP70 gene that quickens of pine in the expression of transcribing with translation skill, and HSP70 is synthetic to be increased thereby make, and makes neurocyte produce tolerance to ischemia, plays protecting neuron from acute.Give birth to mechanism that loose element induces endogenous protection mechanism to start and remain further research, will help understanding to the research of the temporal mode/spatial model of HSP70 protein expression simultaneously its protection mechanism.
Calcium ion is the cell internal information material that extensively exists in the body, effectively effluxes with the enclose inside system by one and keeps the stable of intracellular Ca2+ environment.Since the eighties, the research of the cell function of calcium causes people's common concern, and people recognize Ca gradually
2+Almost influence the physiological activity of cell each side.Ca
2+Trigger many important cellular activities as courier in the cell, as motion, division, pinocytosis, the exocytosis process of cell, the synthetic and decomposition of cyclic adenosine monophosphate and synthetic and release of neurotransmitter and some hormone or the like.
The function of cell depends on the inside and outside calcium ion concentration of cell and maintains a proper proportion.What experimental results show that calcium ion strides stream and intracellular calcium in the film unusually at the time distributes and the time transports the unusual final cell death that causes.Therefore the concentration that detects intracellular calcium not only helps understanding, the diagnosis of disease, the treatment of pathophysiological mechanism in the pair cell damage process, also for exploring the new way that effective medicine provides.Illustrate mechanism of drug action and link.The therapeutical effect that has now proved many medicines is realized by influencing intracellular Ca2+.
In sum, living loose element can improve cerebral ischemia and cause the neurocyte cells injury, and may pass through Calpain, NO, CRP and cross expression of heat shock in the startup brain, and performance is to ischemic tissue of brain, protecting neuron from acute.
Therefore the present invention also relates to and containing as the The compounds of this invention of active ingredient and the pharmaceutical composition of conventional medicine excipient or adjuvant.Usually pharmaceutical composition of the present invention contains the The compounds of this invention of 0.1-95 weight %.
The pharmaceutical composition of The compounds of this invention can be according to method preparation well known in the art.When being used for this purpose, if desired, The compounds of this invention and one or more solids or liquid medicine excipient and/or adjuvant can be combined, make and can be used as suitable administration form or the dosage form that people's medicine or veterinary drug use.
The compounds of this invention or contain its pharmaceutical composition can the unit dosage form administration, route of administration can be intestinal or non-intestinal, as oral, muscle, subcutaneous, nasal cavity, oral mucosa, skin, peritoneum or rectum etc.
The compounds of this invention or the route of administration that contains its pharmaceutical composition can be drug administration by injection.Injection comprises intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection and acupoint injection therapy etc.
Form of administration can be liquid dosage form, solid dosage forms.As liquid dosage form can be true solution class, colloidal type, particulate formulations, emulsion dosage form, mixed suspension form.Other dosage forms are tablet, capsule, drop pill, aerosol, pill, powder, solution, suspensoid, Emulsion, granule, suppository, lyophilized injectable powder etc. for example.
The compounds of this invention can be made ordinary preparation, also can be slow releasing preparation, controlled release preparation, targeting preparation and various particulate delivery system.
For the unit form of administration is made tablet, can be extensive use of various carrier well known in the art.Example about carrier is, for example diluent and absorbent are as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, carbamide, calcium carbonate, kaolin, microcrystalline Cellulose, aluminium silicate etc.; Wetting agent and binding agent are as water, glycerol, Polyethylene Glycol, ethanol, propanol, starch slurry, dextrin, syrup, Mel, glucose solution, mucialga of arabic gummy, gelatine size, sodium carboxymethyl cellulose, lac, methylcellulose, potassium phosphate, polyvinylpyrrolidone etc.; Disintegrating agent, for example dry starch, alginate, agar powder, laminaran, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene sorbitol fatty acid ester, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.; Disintegrate inhibitor, for example sucrose, glyceryl tristearate, cocoa butter, hydrogenation wet goods; Absorption enhancer, for example quaternary ammonium salt, sodium lauryl sulphate etc.; Lubricant, for example Pulvis Talci, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, Polyethylene Glycol etc.Tablet further can also be made coated tablet, for example sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablet and multilayer tablet.
For example, can be extensive use of various carrier well known in the art for pill is made in the administration unit.Example about carrier is, for example diluent and absorbent are as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Kaolin, Pulvis Talci etc.; Binding agent is as arabic gum, Tragacanth, gelatin, ethanol, Mel, liquid sugar, rice paste or batter etc.; Disintegrating agent is as agar powder, dry starch, alginate, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.
For example for capsule is made in the administration unit, the effective ingredient The compounds of this invention is mixed with above-mentioned various carriers, and the mixture that will obtain thus places hard gelatine capsule or soft capsule.Also the effective ingredient The compounds of this invention can be made microcapsule, be suspended in and form suspensoid in the aqueous medium, in the hard capsule of also can packing into or make injection and use.
For example, The compounds of this invention is made injection preparation, as solution, suspensoid solution, Emulsion, lyophilized injectable powder, this preparation can be moisture or non-water, can contain acceptable carrier, diluent, binding agent, lubricant, antiseptic, surfactant or dispersant on a kind of and/or multiple pharmacodynamics.Can be selected from water, ethanol, Polyethylene Glycol, 1 as diluent, the isooctadecanol of ammediol, ethoxylation, the isooctadecanol of polyoxyization, Polyoxyethylene Sorbitol Fatty Acid Esters etc.In addition, ooze injection, can in injection preparation, add proper amount of sodium chloride, glucose or glycerol, in addition, can also add conventional cosolvent, buffer agent, pH regulator agent etc. in order to prepare etc.These adjuvants are that this area is commonly used
In addition, as needs, also can in pharmaceutical preparation, add coloring agent, antiseptic, spice, correctives, sweeting agent or other material.
For reaching the medication purpose, strengthen therapeutic effect, medicine of the present invention or pharmaceutical composition can be with any known medication administrations.
The dosage of The compounds of this invention pharmaceutical composition depends on many factors, for example to prevent or treat the character and the order of severity of disease, the sex of patient or animal, age, body weight, personality and individual reaction, route of administration, administration number of times, therapeutic purposes, therefore therapeutic dose of the present invention can have large-scale variation.In general, the using dosage of Chinese materia medica composition of the present invention is well known to a person skilled in the art.Can be according to the actual drug quantity that is contained in the preparation last in the The compounds of this invention compositions, in addition suitable adjustment to reach the requirement of its treatment effective dose, is finished prevention of the present invention or therapeutic purposes.The suitable dose scope of the every day of The compounds of this invention is preferably the 0.1-100mg/kg body weight, more preferably 1-20mg/kg body weight, more preferably 0.1-100mg/ days/people.Above-mentioned dosage can the single dose form or be divided into several, for example two, three or four dosage form administrations this be subject to administration doctor's clinical experience and comprise the dosage regimen of using other treatment means.
Each treats that required accumulated dose can be divided into repeatedly or by the dose administration.Chemical compound of the present invention or compositions can be taken separately, or merge use and adjust dosage with the other treatment medicine.
Description of drawings
Fig. 1. the shock index of each group in the nervous symptoms scoring experiment.(
* *P<0.001vs. infraction group)
Fig. 2. each group time of staying on hang plate in the hang plate experiment.(
* *P<0.001,
*P<0.01vs. infraction group)
Fig. 3. give birth to the plain influence of pine to ischemia rat cerebral infarction area.
Fig. 4. it is plain to the active influence of LDH in the ischemia rat cerebral tissue to give birth to pine.(
*P<0.05vs. infraction group)
Fig. 5. give birth to pine plain to the active influence of Calpain in the ischemia rat cerebral tissue (
*P<0.05vs. infraction group)
Fig. 6. give birth to the plain influence of pine to the CRP content in the ischemia rat blood serum.(
*P<0.05vs. infraction group)
Fig. 7. give birth to the plain inhibitory action of pine to smooth muscle cell NHE.
Fig. 8. give birth to the plain inhibitory action of pine to astrocyte NHE.
Fig. 9. ischemic region cortex HE (400 *) (A: false processed group that dyes; B: solvent control group; C: pretreated group; D: middle cerebral artery infraction group; E: give birth to loose plain low dose group; F: give birth to loose plain high dose group)
Figure 10. ischemic region Hippocampus CA1 district HE (200 *) (A: false processed group that dyes; B: solvent control group; C: pretreated group; D: middle cerebral artery infraction group; E: give birth to loose plain low dose group; F: give birth to loose plain high dose group)
Figure 11. give birth to expression (200 *) (A: false processed group of loose plain HSP70 at the ischemia cortex; B: solvent control group; C: pretreated group; D: middle cerebral artery infraction group; E: give birth to loose plain low dose group; F: give birth to loose plain high dose group)
Figure 12. give birth to expression (200 *) (A: false processed group of loose plain HSP70 in Hippocampus CA1 district; B: solvent control group; C: pretreated group; D: middle cerebral artery infraction group; E: give birth to loose plain low dose group; F: give birth to loose plain high dose group)
Figure 13. give birth to expression (200 *) (A: false processed group of loose plain HSP27 at the ischemia cortex; B: solvent control group; C: pretreated group; D: middle cerebral artery infraction group; E: give birth to loose plain low dose group; F: give birth to loose plain high dose group)
Figure 14, living pine element are to neuronal cell line PC12 cell H
2O
2Handle the influence of back cell survival.
Figure 15, living pine element are to neuronal cell line PC12 cell H
2O
2Handle the influence that the back discharges lactic acid dehydrogenase
Figure 16. give birth to pine plain to the PC12 neurocyte through H
2O
2Handle the influence of back endocellular liberation calcium concentration
The specific embodiment
The foundation of model: adopt suture method to prepare the middle cerebral artery cerebral infarction models.The SD rat is along cervical region medisection, and separation right side neck is total, neck interior and external carotid artery., internal carotid artery place total in neck closes with the bulldog clamp folder, external carotid artery proximal part and distal end ligation, and cut off the centre.Be pulled to internal carotid artery the external carotid artery free-end in alignment, nylon wire is inserted by external carotid artery, insert back with No. 0 silk thread ligation, hemorrhage to prevent, open internal carotid artery place bulldog clamp, nylon wire is inserted internal carotid artery, continue to be inserted into intracranial, stop when slight resistance, insertion depth is about 2cm.
Grouping and administration: be divided into 5 groups, 10 every group, be respectively: 1) false processed group, 2) the solvent control group; 3) infraction group; 4) low dose group is given birth to loose plain 0.3mgkg
-1Tail vein injection; 5) high dose group is given birth to loose plain 3mgkg
-1Tail vein injection.After experiment finished, rat carried out nervous symptoms scoring and hang plate experiment; The animal broken end is got brain immediately subsequently, detects ischemic areas with the cardinal principle staining.
Neural behavior scoring method and standard are as follows, and mark is high more, illustrate that the behavior disorder of animal is serious more.
Method | | Classification | Mark | |
1. put animal and put animal in smooth flat, push the side respectively with hands in its | Animal reduces to sideway swivel damage back offside muscular strength, easily topples over to offside.It is negative that medial rotation is received 1,2,3 tests in the offside forelimb of damage back | 3 | 6310 |
In nervous symptoms scoring experiment, the nervous symptoms index of false processed group is 0, and the infraction group is 8.8, tangible neurological handicap occurs, gives birth to pine element 3,0.3mgkg
-1Iv.Can significantly improve the nervous symptoms of postoperative, its shock index reduces to 2.40 ± 1.14, and 4.40 ± 1.14 (P<0.001vs. infraction group) (Fig. 1).
In the hang plate experiment, rats with cerebral ischemia time of staying on hang plate is significantly shorter than the sham operated rats animal, and gives birth to pine element 3,0.3mgkg
-1Iv can obviously prolong animal time of staying on hang plate, and its time of staying is respectively 236.00 ± 73.95,105.33 ± 66.83 (P<0.001, P<0.01vs. infraction group).Above presentation of results is given birth to the plain high low dose group of pine and can obviously be improved the behavioristics unusual (Fig. 2) that is caused by cerebral ischemia.
Behind the cerebral ischemia 6h, rat brain can be observed the right side ischemic region and large-area infraction necrosis occurs after TTC dyeing, presents white.The sham operated rats animal brain presents uniform rose, shows ischemic necrosis not occur.The infarct size that high dose group can make cerebral ischemia cause is dwindled (Fig. 3).
Adopt suture method to prepare middle cerebral artery cerebral infarction models (the same), get the ischemic region cerebral tissue and make 1: 10 (W/V) homogenate with ice-cold normal saline ,-20 ℃ of packing are preserved, and carry out biochemistry detection.
Compare with sham operated rats, LDH is active in the ischemia rat cerebral tissue obviously increases.Give birth to loose plain low dose group and can significantly suppress to organize interior LDH activity (P<0.05vs. infraction group), (Fig. 4).
Compare with sham operated rats, Calpain is active in the ischemia rat cerebral tissue obviously increases.Give birth to loose plain high dose group and can significantly suppress to organize interior Calpain activity (P<0.05vs. infraction group), suppression ratio is 22.38% (Fig. 5).
Compare with sham operated rats, the CRP content in the ischemia rat blood serum significantly increases.Give birth to loose plain high dose group and significantly suppress CRP content in the serum (P<0.05vs. infraction group) (Fig. 6).
Under aseptic condition, get thoracic aorta, in Hank ' s liquid, wash blood stains, remove fatty tissue, adventitia and inner membrance, middle film is placed the small beaker that contains culture fluid, be cut into 1mm
2Organize fritter, be inoculated in the culture bottle, arrange by equidistant, add the culture medium that contains 10% hyclone, the jam-pack bottleneck makes piece of tissue be positioned at the culture bottle top, places 37 ℃, 5%CO
2In the incubator, the culture bottle that overturns gently behind the 5h immerses in the culture fluid piece of tissue, leave standstill cultivation then, every 3d changes liquid once, generally grows from the piece of tissue edge at the 4-7d visible cell, grow fine and close cellular layer after 2 weeks, get the cell of cultivating 10-20 generation and be used for experimentation.
Use and give birth to the plain different concentration (10 of pine
-8, 10
-7, 10
-6With 10
-5Mol/L) hatch with rat aorta smooth muscle cell, it is plain 10 wherein to give birth to pine
-7Mol/L is the strongest to the inhibitory action of NHE, is 80.79%, (n=5).The result as shown in Figure 7.
Embodiment 4, the plain inhibitory action of living pine to astrocyte sodium hydrogen exchange (NHE)
Fluorescence indicator BCECF/AM can the interior hydrionic variation of reacting cells.BCECF/AM (no fluorescence) facilitates penetration of cell membrane, is become BCECF (fluorescence is arranged) by the esterase hydrolyzed in the born of the same parents.The fluorescence of BCECF is that pH relies on, and the different fluorescence intensities of pH value are also different.Under certain pH, F
490/ F
450Linear with pH
[16-18]
Behind the cell loading BCECF/AM, by using NH
4Cl stimulates acidify in the inducing cell, and uses high sodium buffer to induce pH to recover.Because no HCO in the cell
3 -Ion is so the recovery of pH is only by the hydrogen exchange body mediation of sodium.Measure under the different condition change in fluorescence of BCECF in the cell.Because acting on of the hydrogen exchange body of sodium recovers to be in the 2min linear behind the cell acidify, so select for use following formula to calculate the hydrogen exchange body suppression ratio of sodium.
PH recovery rate=(R
Recover-R
Acidify)/R
Acidify* 100% (R=F
490/ F
450)
NHE suppression ratio=medicine pH recovery rate/normal control group pH recovery rate * 100%
Newborn 1d rat brachycephaly in super-clean bench is got brain, puts ice-cold D-hank ' s liquid (g/L KCl0.4 KH
2PO
40.06 NaCl 8.0 NaHCO
30.35 Na
2HPO
47H
2O0.06 phenol red 0.02) in divide the bark fetching layer, shred digestion 15min, ice-cold complete medium stops digestion, crosses 200 order cells sieve, 1500rpm is centrifugal, plants in the culture bottle that is covered with 100 μ g/ml poly-D-lysines in advance 5%CO
2, 37 ℃ of CO
2Incubator is cultivated, and changes liquid once in per 3 days.In Day10 culture bottle is put into the isothermal vibration water-bath, 200rpm concussion 18hr is to remove neuron and microglia.Numerous heteroproteose cells that suspending in the culture medium this moment with the culture medium flush away, change with fresh complete medium and cultivate.The cell seeding of purification is gone into 24 holes or 96 well culture plates, cultivates 48hr, carries out GFAP cytochemistry and identifies and test processing.
Test the serum of removing in the astrocyte culture fluid in preceding 24 hours, after the PBS washing, change with serum-free medium.37 ℃ of preheatings of all reagent.In culture medium, add BCECF/AM1.5 μ g/ml 10 μ L, hatch 15min for 37 ℃.Continue to add 50mM NH
4Cl stimulates 10min. not have Na
+(mM choline chloride 140, KCl 3, MgCl for HEPES
21, glucose 10, Hepes20) liquid washes the outer BCECF/AM with the removal born of the same parents, balance 5min, 450nm/490nm excites, and fluorescence is surveyed in the 530nm emission, calculating R=F490/450, the R value is high more, and pH value is high more.(mM NaCl 140, KCl 3, MgCl for high sodium HEPES liquid
21, glucose 10, Hepes 20) flushing is to induce the pH recovery of sodium ion dependence, mensuration fluorescence calculates R=F
490/ F
450With nigericin calibration pH value.
Use and give birth to the plain different concentration (10 of pine
-8, 10
-7, 10
-6With 10
-5Mol/L) hatch with Rat Astroglia.Give birth to the plain inhibitory action of pine and have good dose-effect relationship, its IC NHE
50Be 2.95 * 10
-10Mol/L is far below the IC of DMA
50(n=5), be a more potential NHE inhibitor.As shown in Figure 8.
Obvious damage is not seen in false processed group cortex HE dyeing, and cellularity is complete.Solvent control group and middle cerebral artery infraction group cortical cell are dispersed in, and intercellular substance enlarges, neuron swelling.Pretreated group and medicine high dose group all can significantly be improved the ischemic neuron damage.The result as shown in Figure 9.
False processed group Hippocampus CA1 district HE staining cell level is more, is evenly distributed,, arrange closely, it is clear even to dye, and cellular morphology is complete, no abnormal change.Solvent control group and middle cerebral artery infraction group cell disappearance are obvious, and cell is arranged loose, rarely seen indivedual neurocyte endochylema engrains, karyon pyknosis.The medicine high dose group all can significantly be improved the ischemic neuron damage, and neuron density increases, and it is more even to dye, and cellular morphology is more complete.Result such as Figure 10, table 1.
It is plain to cortex, the painted influence of Hippocampus granule after the cerebral ischemia that table .1. gives birth to pine.
Group | Cortex | Hippocampus |
False processed group solvent control group MCAO IP+MCAO 0.3mg/kg 3mg/kg | ??104.67±8.50 **??63.00±11.27 ??55.00±6.00 ??110.33±11.50 **??60.00±7.00 ??107.67±13.32 ** | ??50.33±5.13 ***??9.33±3.51 ??7.33±2.52 ??42.00±4.36 ***??33.33±9.07 **??50.00±8.00 *** |
*P<0.01,
* *P<0.001vs.MCAO group, and n=3. (meansigma methods ± S.D)
Embodiment 6, the plain influence of living pine to rats with cerebral ischemia cortex and Hippocampus CA1 district HSP70 expression
The false processed group of heat shock protein (HSP) 70 dyeing is not seen cortex dyeing.The expression that is positive of solvent control group, middle cerebral artery infraction group ischemia cortex marginal zone neuron; The dyeing of pretreated group cortex increases the endochylema engrain.Give birth to the loose plain high dose group positive cell number that also can raise and reaching color depth.As shown in figure 11
The HSP70 false processed group that dyes is not seen hippocampus dyeing.The solvent control group, the dyeing of the visible Hippocampus CA1 of the painted pretreated group of middle cerebral artery infraction group positive cell district increases, and brown yellow granule is more common in the endochylema of neuronic cyton and aixs cylinder.Giving birth to loose element can increase positive cell number, and tinctorial strength increases.As Figure 12, shown in the table 2
Table .2. gives birth to the plain influence to rats with cerebral ischemia cortex and Hippocampus CA1 district HSP70 expression of pine
Group | Cortex | Hippocampus |
False processed group solvent control group MCAO IP+MCAO 0.3mg/kg 3mg/kg | ??------ ??0.72±0.05 ??0.66±0.07 ??0.84±0.09 *??0.50±0.10 ??0.82±0.07 * | ??------- ??0.48±0.08 ??0.46±0.05 ??0.69±0.09 *??0.57±0.05 *??0.61±0.07 * |
With the dummy of false processed group as average transmittance mensuration.
*P<0.05vs.MCAO group, and n=3. (meansigma methods ± S.D)
Embodiment 7, living pine element are expressed ischemia rat ischemia cortex, hippocampus HSP27
False processed group is not seen obvious dyeing at whole brain, and middle cerebral artery infraction group HSP27 dyeing strengthens, and pretreated group has dyeing more by force at neuron cell body, and cytochrome significantly increases.It is suitable with middle cerebral artery infraction group number to give birth to the plain high low dose group staining cell of pine.As Figure 13, shown in the table 3.
It is plain to ischemia rat ischemia cortex, hippocampus HSP27 expression that table .3. gives birth to pine.
Group | Cortex |
False processed group solvent control group MCAO IP+MCAO 0.3mg/kg 3mg/kg | ??------ ??0.15±0.04 ??0.20±0.02 ??0.26±0.03 *??0.16±0.05 ??0.22±0.04 |
With the dummy of false processed group as average transmittance mensuration.
*P<0.05vs.MCAO group, and n=3. (meansigma methods ± S.D)
At 37 ℃, 5%CO
2In the constant incubator, cultivate the PC12 cell with 1640 culture medium (containing 10% hyclone, penicillin 100U/ml, streptomycin 100ug/ml).After cell is paved into monolayer, absorb former culture medium, add the H of final concentration 200uM
2O
2100ul experimentizes behind the 24h.Adopt mtt assay to decide cell viability; Adopt LDH to measure LDH Determination on content in the kit measurement culture fluid.The result shows 10
-5Mol/L gives birth to pine element, 10
-6The living loose element of mol/L can obviously suppress the decline of the PC12 cell viability due to the hydrogen peroxide, 10
-5The living loose element of mol/L can reduce the release of the LDH due to the hydrogen peroxide, and hydrogen peroxide is caused the PC12 cell injury protective effect.The results are shown in Figure 14, Figure 15.
Embodiment 9, the plain influence of living pine to free calcium concentration in the neurocyte
Add PC12 cell suspension 90 μ l holes in 96 orifice plates, with 5 μ mol.L
-1Fura-2/AM is at 37 ℃ of isothermal vibration 35min.After load finishes, respectively to contain 0.2% BSA Hanks, not contain Mg
2+0.2% BSA Hanks and D-Hanks liquid wash twice, transferring cell suspension is 2 * 10
6Individual/ml, add 10 in advance
-5After the living Song Suwen of mol/L is incubated 5 minutes, measure the quiescent condition intracellular Ca2+.The maximum excitation wavelength of Fura-2 is 380nm, with Ca
2+In conjunction with after the maximum excitation wavelength be 340nm, emission wavelength is 500nm.Carry out fluoroscopic examination with the FLUO-STAR exometer.Add Triton X-100 broken cell membrane, measure fluorescence behind the concussion mixing, be Ca this moment
2+Fluorescence intensity when saturated.Add EGTA complexation intracellular Ca2+, measure fluorescence behind the concussion mixing, be zero Ca this moment
2+The time fluorescence intensity.
Be calculated as follows Ca
2+Concentration:
[Ca
2+]=KDa*(R-Rmin)/(Rmax-R)*(F
f2/F
b2)?????(R=F
340/F
380)
Drug treating: cell loading adds 10 after finishing in advance
-5After the living Song Suwen of mol/L is incubated 5 minutes, add stimulant KCl respectively, glutamic acid (Glu) and norepinephrine (NE) are measured change in fluorescence immediately.
Experimental result shows 10
-5It is [the Ca of D-Hanks that mol/L gives birth to the outer liquid of loose plain pair cell
2+] not influence of i, when extracellular fluid is Hanks liquid, 10
-5The living pine of mol/L have the effect that reduces the quiescent condition intracellular Ca2+, sees Table 1.10
-5Mol/L gives birth to that stream has inhibitory action in the plain calcium that KCL, NE are caused of pine, and Figure 16 is seen in not influence of stream in the calcium that glutamic acid is caused.
Table 4. is given birth to the plain influence to the quiescent condition intracellular Ca2+ of pine
Handle | ???????????????????[Ca 2+]i(nmol/L) | ||
??Hanks | ??Hanks(Mg 2+free) | ??D-Hanks | |
Contrast | ??114.4±17.1 | ??158.3±18.7 | ??93.2±14.6 * |
Give birth to pine plain 10 -5mol/L | ??91.7±12.7 | ??132.8±11.1 | ??91.0±10.9 * |
Claims (4)
2, according to the application of claim 1, the dosage of wherein said medicine is the loose plain chemical compound of life of 0.1-100mg/kg body weight every day.
3. a pharmaceutical composition that prevents or treat relevant diseases such as cerebral ischemia, cerebral ischemia sequela, neural cell injury and changing function is characterized in that, contains the loose plain chemical compound of the life shown in general formula (I) and the pharmaceutically suitable carrier for the treatment of effective dose.
According to the pharmaceutical composition of claim 2, it is characterized in that 4, described pharmaceutical composition is made into the form of tablet, capsule, pill, injection, slow releasing preparation, controlled release preparation and various particulate delivery systems.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410037860 CN1285334C (en) | 2004-05-12 | 2004-05-12 | Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410037860 CN1285334C (en) | 2004-05-12 | 2004-05-12 | Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1695608A true CN1695608A (en) | 2005-11-16 |
CN1285334C CN1285334C (en) | 2006-11-22 |
Family
ID=35348597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410037860 Expired - Lifetime CN1285334C (en) | 2004-05-12 | 2004-05-12 | Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1285334C (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054512A1 (en) | 2008-11-13 | 2010-05-20 | 石药集团中奇制药技术(石家庄)有限公司 | Two types of crystalline of pinocembrin: α and β, their preparation and their use for manufacture of pharmaceutical compositions |
WO2010066199A1 (en) * | 2008-12-11 | 2010-06-17 | 石药集团中奇制药技术(石家庄)有限公司 | Use of racemates of pinocembrin in preparing medicaments for treating stroke |
CN101307044B (en) * | 2007-05-16 | 2012-07-04 | 中国医学科学院药物研究所 | Two crystallographic form of pinocembrin compounds, preparation method and applications for treating diseases |
CN101537188B (en) * | 2007-03-21 | 2012-07-18 | 中国医学科学院药物研究所 | Pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound |
CN104027337A (en) * | 2014-06-15 | 2014-09-10 | 强红枫 | Medicament composition for treating ischemic cerebrovascular disease and application thereof |
CN106176712A (en) * | 2015-05-25 | 2016-12-07 | 中国医学科学院药物研究所 | The Nuo Sailin medicinal usage in preparation prevention and/or treatment pulmonary hypertension |
US9949946B2 (en) | 2008-11-11 | 2018-04-24 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives |
WO2018090358A1 (en) * | 2016-11-21 | 2018-05-24 | 中国医学科学院药物研究所 | Applications of pinocembrin in preparing anti-cerebral hemorrhage medicament |
-
2004
- 2004-05-12 CN CN 200410037860 patent/CN1285334C/en not_active Expired - Lifetime
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101537188B (en) * | 2007-03-21 | 2012-07-18 | 中国医学科学院药物研究所 | Pinocembrin and cyclodextrin or cyclodextrin derivative inclusion compound |
CN101307044B (en) * | 2007-05-16 | 2012-07-04 | 中国医学科学院药物研究所 | Two crystallographic form of pinocembrin compounds, preparation method and applications for treating diseases |
US9949946B2 (en) | 2008-11-11 | 2018-04-24 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives |
US8399511B2 (en) | 2008-11-13 | 2013-03-19 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Two types of crystalline of pinocembrin, their preparation and their use for manufacture of pharmaceutical compositions |
EA020224B1 (en) * | 2008-11-13 | 2014-09-30 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. | Two types of crystalline of pinocembrin, their preparation and their use for manufacture of pharmaceutical compositions |
EP2360152A4 (en) * | 2008-11-13 | 2012-05-30 | Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd | Two types of crystalline of pinocembrin: a and b, their preparation and their use for manufacture of pharmaceutical compositions |
EP2360152A1 (en) * | 2008-11-13 | 2011-08-24 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Two types of crystalline of pinocembrin: a and b, their preparation and their use for manufacture of pharmaceutical compositions |
KR20110082599A (en) * | 2008-11-13 | 2011-07-19 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | Two types of crystalline of pinocembrin: a and b, their preparation and their use for manufacture of pharmaceutical compositions |
WO2010054512A1 (en) | 2008-11-13 | 2010-05-20 | 石药集团中奇制药技术(石家庄)有限公司 | Two types of crystalline of pinocembrin: α and β, their preparation and their use for manufacture of pharmaceutical compositions |
KR101646805B1 (en) | 2008-11-13 | 2016-08-08 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | : two types of crystalline of pinocembrin: and their preparation and their use for manufacture of pharmaceutical compositions |
JP2012508694A (en) * | 2008-11-13 | 2012-04-12 | 石薬集団中奇制薬技術(石家庄)有限公司 | Two pinocembrins, a process for their production and their use in the production of pharmaceutical compositions |
EA022275B1 (en) * | 2008-12-11 | 2015-12-30 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН) КО., ЛТД. | Use of racemates of pinocembrin in preparing medicaments for treating stroke |
WO2010066199A1 (en) * | 2008-12-11 | 2010-06-17 | 石药集团中奇制药技术(石家庄)有限公司 | Use of racemates of pinocembrin in preparing medicaments for treating stroke |
CN104027337B (en) * | 2014-06-15 | 2016-01-20 | 顾祥茂 | A kind of medical composition and its use for the treatment of ischemic cerebrovascular |
CN104027337A (en) * | 2014-06-15 | 2014-09-10 | 强红枫 | Medicament composition for treating ischemic cerebrovascular disease and application thereof |
CN106176712A (en) * | 2015-05-25 | 2016-12-07 | 中国医学科学院药物研究所 | The Nuo Sailin medicinal usage in preparation prevention and/or treatment pulmonary hypertension |
CN106176712B (en) * | 2015-05-25 | 2020-04-24 | 中国医学科学院药物研究所 | Application of pinocembrin in preparation of medicines for preventing and/or treating pulmonary hypertension |
WO2018090358A1 (en) * | 2016-11-21 | 2018-05-24 | 中国医学科学院药物研究所 | Applications of pinocembrin in preparing anti-cerebral hemorrhage medicament |
Also Published As
Publication number | Publication date |
---|---|
CN1285334C (en) | 2006-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101589026B (en) | Method of treatment of glioma brain tumour | |
CN101626773B (en) | Agent for promoting healing of living body | |
CN1285334C (en) | Application of pinocembrin in preparing medication for treating disease relevant to hurt of nerve cell | |
CN102743739A (en) | Preparation method for blattodea polypeptide substance, and medical use of blattodea polypeptide substance in anti-herpesvirus | |
CN107260710A (en) | The application of cedrol and its derivative in the medicine for promoting the gentle solution alopecia of hair growth is prepared | |
KR101793379B1 (en) | A composition for inhibiting prostate cancer metastasis comprising extract of gleditsia sinensis thorn | |
CN108014109B (en) | Application of the trigonelline in the drug or food that preparation treats or prevents hypoxic damage | |
CN109248177B (en) | Preparation of crocodile amour effective component and application of crocodile amour effective component in oxidation resistance and hepatic fibrosis resistance | |
CN101658522B (en) | Application of tacrine short-chain dimer in preparation of medicament for treating neurodegenerative diseases | |
CN102813914B (en) | Medicinal composition used for treating or preventing cerebrovascular disease and related diseases | |
CN103191119A (en) | Use of itraconazole in inhibiting of Akt kinase (protein kinase B) activity | |
CN110664807A (en) | Pharmaceutical composition with synergistic anti-melanoma efficacy and application thereof | |
CN107468682A (en) | Application of the mangiferin in antiviral drugs is prepared | |
CN102697757B (en) | Application of p-hydroxy benzylidene acetone in preparation of drugs for preventing and/or treating encephalopathy | |
CN1424319A (en) | Dogwood extract and its preparing method and use | |
CN105560302B (en) | Application of geranium water extract in preparation of anti-angiogenesis drugs | |
CN100379417C (en) | Application of sophocarpine in use of making medicines | |
CN106562944A (en) | Applications of FTY720 in preparation of drugs for prevention or treatment of ischemic stroke | |
CN105999245B (en) | Purposes of the pharmaceutical composition containing ulinastatin in preparation treatment gall-bladder cancer drug | |
CN109172824A (en) | A kind of pharmaceutical composition and preparation method thereof for treating cutaneous squamous cell carcinoma | |
CN113116873B (en) | New use of aloe-emodin as anti-mast cell activator | |
CN1733013A (en) | Novel route for administering hairy holly injection and preparation process thereof | |
CN103203009A (en) | New application of partial metabolite of pentapeptide in preparation of myocardial ischemia resistant product | |
CN101116662B (en) | Application of sophocarpine in the preparation of medicine for treating adenovirus-caused inflammation | |
CN102293767B (en) | Application of active natural product B in preparing anti-vascular dementia products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20061122 |